Clinical Trial: Evaluation of MT-12 Implant Survival and Marginal Bone Loss
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Evaluation of MT-12 Implant Survival and Marginal Bone Loss
Brief Summary: The trial is designed as a consecutive enrollment prospective one-center study. A minimum of 30 patients will be included in the study. At implant installation, the patient will be randomized to receive one of the two types of implants (Control: internal hexagon connection implants (CON.INT); Test: Morse taper connection implants (MT-12)). Samples of peri-implant crevicular fluid (PICF) and intrasulcular plaque will be collected at -21 (second-stage surgery), -14 (impressions), 0 (Baseline: prosthesis delivery), 7 days and 1, 3, 6, 12 months. Prosthesis will be fabricated and delivered as usual, i.e., approximately two weeks after the impressions are taken.
Detailed Summary:
Sponsor: Universidad de Granada
Current Primary Outcome: Marginal bone level [ Time Frame: 1 year ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Peri-implant inflammation [ Time Frame: 1 year ]
- Peri-implant microbial contamination [ Time Frame: 1 year ]
Original Secondary Outcome: Same as current
Information By: Universidad de Granada
Dates:
Date Received: November 23, 2016
Date Started: November 2016
Date Completion: June 2018
Last Updated: November 28, 2016
Last Verified: November 2016
